Below are the top 10 fastest-growing Biotech stocks, based on the average
long-term earnings growth rate estimated by Wall Street analysts. One Chinese
company (SHP) is on the list. United Therapeutics Corporation (NASDAQ:UTHR) is
the first fastest-growing stock in this segment of the market. Its long-term
annual EPS growth is expected to be 44.8%. This number is based on the average
estimate of 6 brokerage analysts. Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) is
the second fastest-growing stock in this segment of the market. Its long-term
annual EPS growth is expected to be 31.8%. This number is based on the average
estimate of 4 brokerage analysts. Acorda Therapeutics Inc. (NASDAQ:ACOR) is the
third fastest-growing stock in this segment of the market. Its long-term annual
EPS growth is expected to be 29.7%. This number is based on the average estimate
of 3 brokerage analysts. Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ) is the fourth
fastest-growing stock in this segment of the market. Its long-term annual EPS
growth is expected to be 29.4%. This number is based on the average estimate of
3 brokerage analysts. Celgene Corporation (NASDAQ:CELG) is the fifth
fastest-growing stock in this segment of the market. Its long-term annual EPS
growth is expected to be 25.0%. This number is based on the average estimate of
15 brokerage analysts. ShangPharma Corp (ADR) (NYSE:SHP) is the sixth
fastest-growing stock in this segment of the market. Its long-term annual EPS
growth is expected to be 19.4%. This number is based on the average estimate of
4 brokerage analysts. Meridian Bioscience, Inc. (NASDAQ:VIVO) is the seventh
fastest-growing stock in this segment of the market. Its long-term annual EPS
growth is expected to be 16.8%. This number is based on the average estimate of
5 brokerage analysts. PAREXEL International Corporation (NASDAQ:PRXL) is the
eighth fastest-growing stock in this segment of the market. Its long-term annual
EPS growth is expected to be 16.5%. This number is based on the average estimate
of 8 brokerage analysts. Gilead Sciences, Inc. (NASDAQ:GILD) is the ninth
fastest-growing stock in this segment of the market. Its long-term annual EPS
growth is expected to be 15.8%. This number is based on the average estimate of
13 brokerage analysts. Covance Inc. (NYSE:CVD) is the 10th fastest-growing stock
in this segment of the market. Its long-term annual EPS growth is expected to be
15.4%. This number is based on the average estimate of 10 brokerage analysts.
No comments:
Post a Comment